top of page
AdobeStock_181878464.jpeg

NEXT GENERATION FACTORY
FOR NEXT GENERATION MEDICINE

Modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing

Astraveus is revolutionizing the field of CGT manufacturing with the Lakhesys™ platform, an end-to-end, cell foundry, that uses deep process optimization and single-use, microfluidic bioprocessors to deliver better results with reduced inputs.  
By removing the need for large-scale infrastructure, reducing costs, and overcoming the logistical challenges typically associated with CGT manufacturing, Astraveus is seeking to transform patient access to these life-changing therapies.

Home: Bienvenue

SMALL IS POWERFUL

Therapeutic cells can multiply in the patient's body. This allows them to expand in vivo up to the amounts needed to obtain strong therapeutic effects.


Leveraging this characteristic, our microfluidic cell foundries allow us to optimize and miniaturize cellular therapies and their manufacturing. This way, minute amounts of resources are deployed without compromising efficacy. 

As a result, the cost and environmental impact of these innovative therapies are drastically reduced.

AdobeStock_35338769.jpeg
Home: À propos
Rendu LKS dezoom_edited.png

LAKHESYS

The world’s first microfluidic cell foundry

With an end-to-end microfluidic manufacturing process, Lakhesys is unique.  

At Lakhesys’ innovative core are microfluidic bioprocessors, which mimic organ perfusion and significantly accelerate the molecular exchanges needed to sustain and transform cells into potent therapeutic agents.


Once the process is optimized, Lakhesys allows us to produce massively in parallel, up to 100 minibatches simultaneously in a conventional size manufacturing room.  

Lakhesys allows better results with fewer reduced inputs through increased mass transfer, precise control and minimized waste, resulting in higher quality products obtained at lower cost and reduced environmental impact.  

Astraveus is supported by France and the European Union

Astraveus has received funding from the European Union's Horizon 2020 research and innovation programme, under grant agreement N° 850358, and from the French Minister of Education and Innovation and BPI France as part of i-Lab prize.

Home: Image

APPLICATIONS

Lakhesys supports the development and manufacturing of most types of cell and gene therapies, including:

Cytotoxic vesicle_edited.jpg

CAR-T

In healthy patients, T cells detect and kill sick cells. Cancer cells escape T cells recognition thanks to mutations.  
CAR-T cells (T cells equipped with a Chimeric Antigen Receptor) are artificially hardcoded to recognize and kill cancer cells. 
Multiple CAR-T therapies are commercially available, but their access is limited by low manufacturing throughput and high prices.

HSC

Hematopoietic stem cells (HSCs) are mothers to all blood cells including erythrocytes and lymphocytes. 
Genetically engineering HSCs allows patients to produce blood cells with new or corrected functions. 
Genetically engineered HSC have a proven potential to cure certain hemoglobinopathies and immune deficiencies.

AdobeStock_276496476.jpeg
Home: Projets
Toutes les mains dans

WORK WITH US

If you wish to discuss partnering,
please contact us at: contact@astraveus.com

Home: À propos de nous

TEAM

Home: Membres de l'Équipe
JL.PNG

CEO

DR JÉRÉMIE LAURENT

CAREERS

We're always interested in hearing from motivated, talented individuals.
Our current openings are below. If you don't find a suitable role, but believe you could be a strong addition to our team, please send your resume to apply@astraveus.com 

SOFTWARE ENGINEER

ELECTRONICS ENGINEER

SINGLE USE SYSTEMS ENGINEER

Home: Liste
supportzoomed.png

PARTNERS & SUPPORTERS

Home: Bienvenue

CONTACT

We are based in Saint Louis, Hospital, downtown Paris.

1, Avenue Claude Vellefaux
Hôpital Saint-Louis, Centre MEARY
75010 Paris, France

Home: Contact
bottom of page